Global Male Hypogonadism Market 2022 - AbbVie Inc., Allergan plc, AstraZeneca plc, Bayer AG, Eli Lilly and Company Ltd., Endo International plc, Merck & Co., Inc.

Global Male Hypogonadism Market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% from 2016 to 2022. The pituitary disorders segment accounted for nearly half of the total market share in 2015, and is expected to maintain its dominance during analysis period as well.

Male hypogonadism is a clinical condition in which testes cannot produce enough testosterone, resulting in decreased development of muscle mass, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice. Growth in the male hypogonadism market is driven by the rise in prevalence & incidence of men with testosterone deficiency, increase in infertility rates, and growth in awareness among the patient population about hypogonadism treatment options by certain campaigns carried out by the government.

Moreover, the risk of hypogonadism is very high in the geriatric population, and population with obesity & diabetes; thus, growth in geriatric population and incidence of chronic lifestyle disorders, such obesity & diabetes, are further expected to boost the market growth. However, high side effects of all testosterone products are expected to hinder growth of the testosterone replacement therapy (TRT) segment in this market. Technological advancements are expected to provide new opportunities during the forecast period.

Also you can request for sample pdf with more details and graph: https://www.alliedmarketresearch.com/request-sample/1874

List of Key Players Profiled in the Report

• AbbVie Inc.
• Allergan plc
• Astrazeneca plc
• Bayer AG
• Eli Lilly and Company Ltd.
• Endo International plc.
• Merck & Co., Inc.
• Ferring
• Finox Biotech,
• IBSA Institut Biochimque SA
• Laboratoires Genevrier
• Teva Pharmaceutical Industries Ltd.

List of other Players in the Value Chain (These players are not profiled in the report. The same will be included on request.)

• Lipocine Inc.
• Pfizer Inc.
• Aytu Biosciences
• Diurnal Group PLC
• Hyundai Pharmaceuticals Co Ltd.
• Perrigo Company plc
• Novus Biologicals, LLC

North America accounted for majority of the share (more than three-fourths) in the market in 2015, and is expected to remain dominant throughout the forecast period. This is due to growth in population suffering from primary and secondary causes of hypogonadism, and increased patient awareness about the availability of treatment options. In addition, high adoption rate of technologically advanced products and presence of highly sophisticated healthcare infrastructure are anticipated to create new growth opportunities for key players in this market.

Europe was the second leading market in 2015. However, Asia-Pacific is expected to be register the highest CAGR of 7.2% throughout the analysis period, owing to rise in hypogonadism patient population along with increase in adoption of western lifestyle, unhealthy diet habits, and growth in urbanization.

Key Findings of the Male Hypogonadism Market

• By drug therapy, gonadotropin and gonadotropin-releasing hormones therapy segment is projected to grow at the highest CAGR of 8.9% during the forecast period.
• Pituitary disorders segment is expected to grow at the CAGR of 3.2%.
• Injectables accounted for nearly half of the market share in 2015.
• North America accounted for majority of the share (more than three-fourths) in 2015, and is expected to remain dominant throughout the forecast period.
• U.S. accounted for the majority share in the North American market in 2015, and the Mexican market is expected to grow at the highest CAGR of 6.7%.

LIST OF TABLES

TABLE 1. MALES BEING TREATED FOR HYPOGONADISM, (VOLUME), 2014-2022 (MILLION)
TABLE 2. MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 ($MILLION)
TABLE 3. TESTOSTERONE REPLACEMENT THERAPY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4. GONADOTROPINS AND GONADOTROPINS RELEASING HORMONES THERAPY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 5. MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 ($MILLION)
TABLE 6. TOPICAL GEL MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7. INJECTABLES MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8. TRANSDERMAL PATCHES MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9. OTHERS MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 10. MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 11. MALE HYPOGONADISM MARKET FOR KLINEFELTER'S SYNDROME, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12. MALE HYPOGONADISM MARKET FOR PITUITARY DISORDERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13. MALE HYPOGONADISM MARKET FOR KALLMANN SYNDROME, BY GEOGRAPHY 2014-2022 ($MILLION)
TABLE 14. MALE HYPOGONADISM MARKET FOR OTHER SYNDROMES, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15. MALE HYPOGONADISM MARKET, BY REGION, 2014-2022 ($MILLION)
.
.
TABLE 54. TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 55. TEVA PHARMACEUTICAL: OPERATING SEGMENTS

Browse here for full report with Toc: https://www.alliedmarketresearch.com/male-hypogonadism-market

About Us:
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:
Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.